COGT — Cogent Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's
U.S. STOCKS ON THE MOVE-Dave, Quanta Services, Union Pacific Corp
U.S. STOCKS ON THE MOVE-Dollar Tree, Kohl's, Oil companies
Cogent rises as US FDA accepts marketing application for cancer drug
Brief: Cogent Biosciences Says FDA Accepts NDA With Priority Review For Bezuclastinib In Combination With Sunitinib
Cogent Biosciences Q1 net loss widens on higher expenses
U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia
U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp
U.S. STOCKS ON THE MOVE-Intuit, Acumen, Circle,
Cogent Biosciences rises after US FDA agrees to review rare‑disease drug
Brief: Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Cogent Biosciences Q4 net loss widens
Brief: Cogent Biosciences Q4 Operating Expenses USD 99.493 Million
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
Brief: Cogent Biosciences Announces Presentation At The 44Th Annual J.P. Morgan Healthcare Conference